• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4657932)   Today's Articles (3969)   Subscriber (51250)
For: Coplan PM, Chilcoat HD, Butler SF, Sellers EM, Kadakia A, Harikrishnan V, Haddox JD, Dart RC. The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting. Clin Pharmacol Ther 2016;100:275-86. [PMID: 27170195 PMCID: PMC5102571 DOI: 10.1002/cpt.390] [Citation(s) in RCA: 50] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2016] [Revised: 04/01/2016] [Accepted: 05/04/2016] [Indexed: 01/14/2023]
Number Cited by Other Article(s)
1
Delcher C, Smith AL, Romanelli F, Gaskill L, Surratt HL. Oxymorphone and Oxycodone Pharmacy Purchases in US Counties: Prelude to the Largest Rural Human Immunodeficiency Virus Outbreak in US History. Pharmacoepidemiol Drug Saf 2024;33:e70066. [PMID: 39623517 DOI: 10.1002/pds.70066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2024] [Revised: 11/04/2024] [Accepted: 11/09/2024] [Indexed: 12/19/2024]
2
Webster L, Gudin J. Review of Opioid Abuse-Deterrent Formulations: Impact and Barriers to Access. J Pain Res 2024;17:1989-2000. [PMID: 38854928 PMCID: PMC11162618 DOI: 10.2147/jpr.s457982] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2024] [Accepted: 05/06/2024] [Indexed: 06/11/2024]  Open
3
Gad SF, Vasiukhina A, Keller JS, Solorio L, Yeo Y. Multidimensional opioid abuse deterrence using a nanoparticle-polymer hybrid formulation. J Control Release 2024;370:490-500. [PMID: 38685384 PMCID: PMC11162896 DOI: 10.1016/j.jconrel.2024.04.046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2024] [Revised: 04/16/2024] [Accepted: 04/25/2024] [Indexed: 05/02/2024]
4
Severtson SG, Haanschoten EE, Iwanicki J, Dart RC. Differences in severity of poison centers exposures involving XTAMPZA® ER versus other opioid analgesics. Pain Manag 2023;13:519-527. [PMID: 37850331 DOI: 10.2217/pmt-2022-0068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2023]  Open
5
Kentucky Pharmacists’ Experiences Dispensing Abuse Deterrent Opioid Analgesics. J Am Pharm Assoc (2003) 2022;62:1836-1842. [DOI: 10.1016/j.japh.2022.07.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2022] [Revised: 07/28/2022] [Accepted: 07/28/2022] [Indexed: 11/18/2022]
6
Dickson-Gomez J, Krechel S, Spector A, Weeks M, Ohlrich J, Green Montaque HD, Li J. The effects of opioid policy changes on transitions from prescription opioids to heroin, fentanyl and injection drug use: a qualitative analysis. Subst Abuse Treat Prev Policy 2022;17:55. [PMID: 35864522 PMCID: PMC9306091 DOI: 10.1186/s13011-022-00480-4] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/10/2022] [Indexed: 11/28/2022]  Open
7
Beachler DC, Hall K, Garg R, Banerjee G, Li L, Boulanger L, Yuce H, Walker AM. An Evaluation of the Effect of the OxyContin Reformulation on Unintentional Fatal and Nonfatal Overdose. Clin J Pain 2022;38:396-404. [PMID: 35356897 PMCID: PMC9076252 DOI: 10.1097/ajp.0000000000001034] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2021] [Revised: 02/10/2022] [Accepted: 02/19/2022] [Indexed: 12/04/2022]
8
Delcher C, Bae J, Wang Y, Doung M, Fink DS, Young HW. Defining "Doctor shopping" with Dispensing Data: A Scoping Review. PAIN MEDICINE 2021;23:1323-1332. [PMID: 34931686 DOI: 10.1093/pm/pnab344] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/30/2021] [Revised: 12/14/2021] [Accepted: 12/14/2021] [Indexed: 11/13/2022]
9
Paljarvi T, Strang J, Quinn PD, Luciano S, Fazel S. Abuse-deterrent extended-release oxycodone and risk of opioid-related harm. Addiction 2021;116:2409-2415. [PMID: 33394528 PMCID: PMC8363193 DOI: 10.1111/add.15392] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/26/2020] [Revised: 08/05/2020] [Accepted: 12/23/2020] [Indexed: 01/05/2023]
10
Gadd S, Cox N, Samuelson J, Kenney A, Turner K, Cochran G. Abuse-Deterrent Opioid Formulations and the Opioid Crisis: A Pharmacist's Perspective. Ther Drug Monit 2021;43:35-41. [PMID: 33278243 DOI: 10.1097/ftd.0000000000000844] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2020] [Accepted: 11/04/2020] [Indexed: 11/26/2022]
11
Butler SF, Faraone SV, Rostain AL, Newcorn JH, Antshel KM, Robbins RS, Green JL. Non-medical Use of Prescription Stimulants Among College Students: Non-oral Routes of Administration, Risk Factors, Motivations, and Pathways. Front Psychiatry 2021;12:667118. [PMID: 34483980 PMCID: PMC8415354 DOI: 10.3389/fpsyt.2021.667118] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/12/2021] [Accepted: 07/19/2021] [Indexed: 11/13/2022]  Open
12
Nolan ML, Harocopos A, Allen B, Paone D. Reformulation of oxycodone 80 mg to prevent misuse: A cohort study assessing the impact of a supply-side intervention. THE INTERNATIONAL JOURNAL OF DRUG POLICY 2020;83:102848. [DOI: 10.1016/j.drugpo.2020.102848] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2019] [Revised: 06/11/2020] [Accepted: 06/29/2020] [Indexed: 11/29/2022]
13
Maddox D, Deschner B, Goodsun D, Lapiz-Bluhm MD. Veterans Team Recovery Integrative Immersion Process (Vet TRIIP): A Qualitative Evaluation of Participation and Impact. Mil Med 2020;185:e1284-e1289. [PMID: 32236440 DOI: 10.1093/milmed/usaa053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2019] [Revised: 02/06/2020] [Accepted: 02/28/2020] [Indexed: 11/14/2022]  Open
14
Smart R, Kase CA, Taylor EA, Lumsden S, Smith SR, Stein BD. Strengths and weaknesses of existing data sources to support research to address the opioids crisis. Prev Med Rep 2020;17:101015. [PMID: 31993300 PMCID: PMC6971390 DOI: 10.1016/j.pmedr.2019.101015] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2019] [Revised: 10/22/2019] [Accepted: 11/02/2019] [Indexed: 12/18/2022]  Open
15
Rossiter LF, Kwong WJ, Marrett E. Healthcare Resource Use and Cost: The Impact of Adopting an Abuse-Deterrent Formulation of Extended Release Morphine. CLINICOECONOMICS AND OUTCOMES RESEARCH 2020;12:35-44. [PMID: 32021338 PMCID: PMC6974417 DOI: 10.2147/ceor.s226607] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2019] [Accepted: 11/08/2019] [Indexed: 12/03/2022]  Open
16
Balyan R, Hahn D, Huang H, Chidambaran V. Pharmacokinetic and pharmacodynamic considerations in developing a response to the opioid epidemic. Expert Opin Drug Metab Toxicol 2020;16:125-141. [PMID: 31976778 PMCID: PMC7199505 DOI: 10.1080/17425255.2020.1721458] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2019] [Accepted: 01/22/2020] [Indexed: 12/14/2022]
17
Kawamata M, Iseki M, Kawakami M, Yabuki S, Sasaki T, Ishida M, Nishiyori A, Hida H, Kikuchi SI. Efficacy And Safety Of Controlled-Release Oxycodone For The Management Of Moderate-To-Severe Chronic Non-Cancer Pain In Japanese Patients: Results From An Open-Label Study. J Pain Res 2019;12:3423-3436. [PMID: 31920367 PMCID: PMC6934115 DOI: 10.2147/jpr.s210502] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2019] [Accepted: 10/19/2019] [Indexed: 01/20/2023]  Open
18
Yenikomshian MA, White AG, Carson ME, Jia ZB, Mendoza MR, Roland CL. Modeling the potential impact of abuse-deterrent opioids on medical resource utilization. J Med Econ 2019;22:1073-1079. [PMID: 31314616 DOI: 10.1080/13696998.2019.1645680] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
19
Butler SF, Black RA, Fleming AB. Relative Abuse of Crush-Resistant Prescription Opioid Tablets via Alternative Oral Modes of Administration. PAIN MEDICINE 2019;19:1613-1627. [PMID: 29016905 PMCID: PMC6084581 DOI: 10.1093/pm/pnx151] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
20
Tyndale RF, Sellers EM. Opioids: The Painful Public Health Reality. Clin Pharmacol Ther 2019;103:924-935. [PMID: 29878319 DOI: 10.1002/cpt.1074] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2018] [Accepted: 03/19/2018] [Indexed: 12/28/2022]
21
Chisholm-Burns MA, Spivey CA, Sherwin E, Wheeler J, Hohmeier K. The opioid crisis: Origins, trends, policies, and the roles of pharmacists. Am J Health Syst Pharm 2019;76:424-435. [DOI: 10.1093/ajhp/zxy089] [Citation(s) in RCA: 44] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]  Open
22
Peacock A, Larance B, Bruno R, Pearson SA, Buckley NA, Farrell M, Degenhardt L. Post-marketing studies of pharmaceutical opioid abuse-deterrent formulations: a framework for research design and reporting. Addiction 2019;114:389-399. [PMID: 29989247 PMCID: PMC6599581 DOI: 10.1111/add.14380] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/15/2017] [Revised: 02/12/2018] [Accepted: 07/04/2018] [Indexed: 12/01/2022]
23
Dalal S, Bruera E. Pain Management for Patients With Advanced Cancer in the Opioid Epidemic Era. Am Soc Clin Oncol Educ Book 2019;39:24-35. [PMID: 31099619 DOI: 10.1200/edbk_100020] [Citation(s) in RCA: 58] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
24
Burtner J, Behling M, Cassidy T, Butler SF. Prevalence of nonmedical use and routes of administration for prescription stimulant medications among adults in a substance abuse treatment population. J Addict Dis 2018;37:34-45. [PMID: 30592231 DOI: 10.1080/10550887.2018.1512825] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
25
Ahmad R, Alaei S, Omidian H. Safety and performance of current abuse-deterrent formulations. Expert Opin Drug Metab Toxicol 2018;14:1255-1271. [DOI: 10.1080/17425255.2018.1546289] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
26
Joshi Y, Muppalaneni S, Omidian A, Mastropietro DJ, Omidian H. Determining Abuse Deterrence Performance of Poly (ethylene oxide) Using a Factorial Design. Adv Pharm Bull 2018;8:495-505. [PMID: 30276147 PMCID: PMC6156473 DOI: 10.15171/apb.2018.058] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2017] [Revised: 06/06/2018] [Accepted: 06/20/2018] [Indexed: 12/30/2022]  Open
27
Crudele N, Giordano J. Comment on Mayock SP, Saim S, Fleming AB. In Vitro Drug Release After Crushing: Evaluation of Xtampza® ER and Other ER Opioid Formulations. Clin Drug Investig 2018;38:795-797. [PMID: 29949103 PMCID: PMC6061400 DOI: 10.1007/s40261-018-0663-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
28
Kinzler ER, Pantaleon C, Aigner S. Relative Oral Bioavailability of an Abuse-deterrent, Extended-release Formulation of Morphine Versus Extended-release Morphine: A 2-period, Single-dose, Randomized Crossover Study in Healthy Subjects. Clin Ther 2018;40:1357-1365. [PMID: 30049503 DOI: 10.1016/j.clinthera.2018.06.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2018] [Revised: 06/07/2018] [Accepted: 06/13/2018] [Indexed: 11/24/2022]
29
Nalamachu SR, Shah B. Abuse of immediate-release opioids and current approaches to reduce misuse, abuse, and diversion. Postgrad Med 2018;134:388-394. [DOI: 10.1080/00325481.2018.1502569] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
30
Cheng HG, Coplan PM. Incidence of nonmedical use of OxyContin and other prescription opioid pain relievers before and after the introduction of OxyContin with abuse deterrent properties. Postgrad Med 2018;130:568-574. [PMID: 29978755 DOI: 10.1080/00325481.2018.1495541] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
31
Possible Opioid Shopping and its Correlates. Clin J Pain 2018;33:976-982. [PMID: 28145912 DOI: 10.1097/ajp.0000000000000483] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
32
Pergolizzi JV, Taylor R, LeQuang JA, Raffa RB. What’s holding back abuse-deterrent opioid formulations? Considering 12 U.S. stakeholders. Expert Opin Drug Deliv 2018;15:567-576. [DOI: 10.1080/17425247.2018.1473374] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
33
Abuse-deterrent Opioid Formulations. Anesthesiology 2018;128:1015-1026. [DOI: 10.1097/aln.0000000000002031] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
34
Intranasal Pharmacokinetics of Morphine ARER, a Novel Abuse-Deterrent Formulation: Results from a Randomized, Double-Blind, Four-Way Crossover Study in Nondependent, Opioid-Experienced Subjects. Pain Res Manag 2018;2018:7276021. [PMID: 29849845 PMCID: PMC5937443 DOI: 10.1155/2018/7276021] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2017] [Revised: 03/01/2018] [Accepted: 03/25/2018] [Indexed: 11/17/2022]
35
Rose ME. Are Prescription Opioids Driving the Opioid Crisis? Assumptions vs Facts. PAIN MEDICINE (MALDEN, MASS.) 2018;19:793-807. [PMID: 28402482 PMCID: PMC6018937 DOI: 10.1093/pm/pnx048] [Citation(s) in RCA: 67] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
36
Pergolizzi JV, Raffa RB, Taylor R, Vacalis S. Abuse-deterrent opioids: an update on current approaches and considerations. Curr Med Res Opin 2018;34:711-723. [PMID: 29262730 DOI: 10.1080/03007995.2017.1419171] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
37
Improving the Clinical Pharmacologic Assessment of Abuse Potential: Part 2: Optimizing the Design of Human Abuse Potential Studies. J Clin Psychopharmacol 2018;38:113-118. [PMID: 29360651 DOI: 10.1097/jcp.0000000000000838] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
38
Volkow N, Benveniste H, McLellan AT. Use and Misuse of Opioids in Chronic Pain. Annu Rev Med 2018;69:451-465. [PMID: 29029586 DOI: 10.1146/annurev-med-011817-044739] [Citation(s) in RCA: 170] [Impact Index Per Article: 28.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
39
Understanding abuse of buprenorphine/naloxone film versus tablet products using data from ASI-MV® substance use disorder treatment centers and RADARS® System Poison Centers. J Subst Abuse Treat 2018;84:42-49. [DOI: 10.1016/j.jsat.2017.10.010] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2017] [Revised: 10/23/2017] [Accepted: 10/25/2017] [Indexed: 11/18/2022]
40
Knezevic NN, Yekkirala A, Yaksh TL. Basic/Translational Development of Forthcoming Opioid- and Nonopioid-Targeted Pain Therapeutics. Anesth Analg 2017;125:1714-1732. [PMID: 29049116 PMCID: PMC5679134 DOI: 10.1213/ane.0000000000002442] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
41
Bucher Bartelson B, Le Lait MC, Green JL, Cepeda MS, Coplan PM, Maziere JY, Wedin GP, Dart RC. Changes in misuse and abuse of prescription opioids following implementation of Extended-Release and Long-Acting Opioid Analgesic Risk Evaluation and Mitigation Strategy. Pharmacoepidemiol Drug Saf 2017;26:1061-1070. [DOI: 10.1002/pds.4257] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2016] [Revised: 05/10/2017] [Accepted: 06/12/2017] [Indexed: 11/08/2022]
42
Vosburg SK, Haynes C, Besharat A, Green JL. Changes in drug use patterns reported on the web after the introduction of ADF OxyContin: findings from the Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS) System Web Monitoring Program. Pharmacoepidemiol Drug Saf 2017;26:1044-1052. [DOI: 10.1002/pds.4248] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2016] [Revised: 04/26/2017] [Accepted: 06/05/2017] [Indexed: 11/08/2022]
43
Breaking barriers to novel analgesic drug development. Nat Rev Drug Discov 2017;16:545-564. [PMID: 28596533 DOI: 10.1038/nrd.2017.87] [Citation(s) in RCA: 204] [Impact Index Per Article: 29.1] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
44
O'Neill R, Lor K, Pruskowski J. Abuse-Deterrent Opioid Formulations #329. J Palliat Med 2017;20:676-678. [DOI: 10.1089/jpm.2017.0088] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]  Open
45
Green JL, Bucher Bartelson B, Le Lait MC, Roland CL, Masters ET, Mardekian J, Bailey JE, Dart RC. Medical outcomes associated with prescription opioid abuse via oral and non-oral routes of administration. Drug Alcohol Depend 2017;175:140-145. [PMID: 28414990 DOI: 10.1016/j.drugalcdep.2017.01.039] [Citation(s) in RCA: 39] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/16/2016] [Revised: 01/13/2017] [Accepted: 01/14/2017] [Indexed: 11/29/2022]
46
Crudele NT, Giordano J, Kapil RP, Randhawa AS. In response to Gudin et al. - Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties. PAIN MEDICINE 2017;18:990-991. [PMID: 28034984 PMCID: PMC5431380 DOI: 10.1093/pm/pnw278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
47
Poon KKS, Wong SHS. New and developing anesthesia drugs. Expert Opin Pharmacother 2017;18:195-204. [DOI: 10.1080/14656566.2017.1280461] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
48
Roland CL, Setnik B, Brown DA. Assessing the impact of abuse-deterrent opioids (ADOs): identifying epidemiologic factors related to new entrants with low population exposure. Postgrad Med 2016;129:12-21. [PMID: 27960575 DOI: 10.1080/00325481.2017.1272397] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
49
Webster LR, Markman J, Cone EJ, Niebler G. Current and future development of extended-release, abuse-deterrent opioid formulations in the United States. Postgrad Med 2016;129:102-110. [DOI: 10.1080/00325481.2017.1268902] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
50
Kopecky EA, Fleming AB, Levy-Cooperman N, O'Connor M, M Sellers E. Oral Human Abuse Potential of Oxycodone DETERx® (Xtampza® ER). J Clin Pharmacol 2016;57:500-512. [PMID: 27669664 PMCID: PMC5363337 DOI: 10.1002/jcph.833] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2016] [Accepted: 09/20/2016] [Indexed: 11/10/2022]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA